SIGA Technologies Inc (SIGA)vsTeva Pharma Industries Ltd ADR (TEVA)
SIGA
SIGA Technologies Inc
$5.00
+0.20%
HEALTHCARE · Cap: $357.51M
TEVA
Teva Pharma Industries Ltd ADR
$29.46
+1.10%
HEALTHCARE · Cap: $33.94B
Smart Verdict
WallStSmart Research — data-driven comparison
Teva Pharma Industries Ltd ADR generates 18148% more annual revenue ($17.26B vs $94.58M). SIGA leads profitability with a 24.6% profit margin vs 8.2%. TEVA appears more attractively valued with a PEG of 1.43. TEVA earns a higher WallStSmart Score of 73/100 (B).
SIGA
Buy54
out of 100
Grade: C-
TEVA
Strong Buy73
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+55.7%
Fair Value
$14.98
Current Price
$5.00
$9.98 discount
Margin of Safety
+39.4%
Fair Value
$56.63
Current Price
$29.46
$27.17 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Keeps 25 of every $100 in revenue as profit
Attractively priced relative to earnings
Reasonable price relative to book value
Every $100 of equity generates 21 in profit
Strong operational efficiency at 27.3%
Earnings expanding 40.0% YoY
Generating 1.0B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
Weak financial health signals
Expensive relative to growth rate
Revenue declined 95.3%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : SIGA
The strongest argument for SIGA centers on Debt/Equity, Altman Z-Score, Profit Margin. Profitability is solid with margins at 24.6% and operating margin at -2.5%.
Bull Case : TEVA
The strongest argument for TEVA centers on Return on Equity, Operating Margin, EPS Growth. Revenue growth of 11.4% demonstrates continued momentum. PEG of 1.43 suggests the stock is reasonably priced for its growth.
Bear Case : SIGA
The primary concerns for SIGA are Market Cap, Piotroski F-Score, PEG Ratio.
Bear Case : TEVA
The primary concerns for TEVA are Altman Z-Score.
Key Dynamics to Monitor
SIGA profiles as a declining stock while TEVA is a value play — different risk/reward profiles.
SIGA carries more volatility with a beta of 0.99 — expect wider price swings.
TEVA is growing revenue faster at 11.4% — sustainability is the question.
TEVA generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
TEVA scores higher overall (73/100 vs 54/100) and 11.4% revenue growth. SIGA offers better value entry with a 55.7% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
SIGA Technologies Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health safety and infectious disease markets in the United States. The company is headquartered in New York, New York.
Visit Website →Teva Pharma Industries Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?